Sales Growth of New Pharmaceuticals Across the Globe: The Role of Regulatory Regimes

Stremersch, Stefan; Lemmens, Aurélie
July 2009
Marketing Science;Jul/Aug2009, Vol. 28 Issue 4, p690
Academic Journal
Prior marketing literature has overlooked the role of regulatory regimes in explaining international sales growth of new products. This paper addresses this gap in the context of new pharmaceuticals (15 new molecules in 34 countries) and sheds light on the effects of regulatory regimes on new drug sales across the globe. Based on a time-varying coefficient model, we find that differences in regulation substantially contribute to cross-country variation in sales. One of the regulatory constraints investigated, i.e., manufacturer price controls, has a positive effect on drug sales. The other forms of regulation such as restrictions of physician prescription budgets and the prohibition of direct-to-consumer advertising (DTCA) tend to hurt sales. The effect of manufacturer price controls is similar for newly launched and mature drugs. By contrast, regulations on physician prescription budgets and DTCA have a differential effect for newly launched and mature drugs. Whereas the former hurts mature drugs more, the latter has a larger effect on newly launched drugs. In addition to these regulatory effects, we find that national culture, economic wealth, and lagged sales also affect drug sales. Our findings may be used as input by managers for international launch and marketing decisions. They may also be used by public policy administrators to assess the role of regulatory regimes in pharmaceutical sales growth.


Related Articles

  • PHARMACEUTICAL PRICING AND REIMBURSEMENT POLICIES IN SWITZERLAND. Paris, Valérie; Docteur, Elizabeth // OECD Papers;2007, Vol. 7 Issue 6, p1 

    The article assesses the economic policies of Switzerland specially its pharmaceutical pricing and reimbursement policies. Such assessment, accordingly, is in line with the assessing of the direct impact of the policies of the country as well. It is claimed that the country's pharmaceutical...

  • SALUD Y ALIMENTACIÓN.  // Actualidad Juridica (1578-956X);2014, Issue 37, p296 

    No abstract available.

  • New law in Germany working.  // PharmacoEconomics & Outcomes News;3/17/2012, Issue 649, p3 

    The article reports on the implementation of a law that fixes drug prices in Germany.

  • New German drug law: towards value-based pricing?  // PharmacoEconomics & Outcomes News;7/9/2011, Issue 632, p3 

    This article discusses the introduction of a drug pricing law by the German government in January 2011.

  • Maine Rx price law running into heavy weather. Conlan, Michael F. // Drug Topics;9/18/2000, Vol. 144 Issue 18, p90 

    Talks about Maine's proposed prescription drug price reduction law. Impact on pharmaceutical companies that are shipping products to Maine; Remarks from Kevin W. Concannon, commissioner of Maine's Department of Human Services, regarding techniques to stop Maine's efforts to reduce the prices of...

  • Germany caps drug prices. Mitchell, Peter // Nature Biotechnology;Feb2011, Vol. 29 Issue 2, p96 

    The article reports on a law implemented in Germany which control the price of newly licensed medicine.

  • Drug price controls: Will the nation go as Maine goes?  // Medical Marketing & Media;Dec2000, Vol. 35 Issue 12, p6 

    Focuses on the implication of a Maine federal court's issuance of a preliminary injunction against some part of the state's drug price control law on the national price control policy. Statewide variations in price control laws; Criticisms on Maine's drug price regulation policy.

  • Making Sense of Drug Prices. Danzon, Patricia M. // Regulation;2000, Vol. 23 Issue 1, p56 

    Deals with regulation of drug prices in the United States. Why drug prices might be lower in Canada than in the United States; Price discounting as a common business strategy; Benefits of price differentials.

  • Drug prices to be evaluated. Aiyar, Sharada // Chemical Business;Aug97, Vol. 11 Issue 1, p50 

    Reports that India's Bureau of Industrial Costs and Prices (BICP) Ministry of Industry, has undertaken a cost price study of bulk drugs under provisions of the Drug Prices Control Order, 1995. Names of the bulk drugs under study; Another action done by the bureau in connection with the cost...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics